Cargando…
Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma
Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limita...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885548/ https://www.ncbi.nlm.nih.gov/pubmed/35242707 http://dx.doi.org/10.3389/fonc.2022.805978 |
_version_ | 1784660448290799616 |
---|---|
author | Wu, Kunzhe Yu, Beibei Li, Di Tian, Yangyang Liu, Yan Jiang, Jinlan |
author_facet | Wu, Kunzhe Yu, Beibei Li, Di Tian, Yangyang Liu, Yan Jiang, Jinlan |
author_sort | Wu, Kunzhe |
collection | PubMed |
description | Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limitations, novel therapeutic modalities for OS treatment using nanometer-sized platform-based chemotherapeutic delivery have emerged as a promising alternative therapy. This form of therapy offers multiple advantages, such as accurate delivery of the drug to the tumor site and repair of limited bone defects after tumor resection. In this review, we briefly summarize nanoplatforms, including liposomes, polymeric nanoparticles, inorganic nanoparticles, nanomicelles, dendrimers, nanocapsules, and exosomes. The essential shortcomings involved in these nanoplatforms, such as poor stability, immunogenicity, insufficient circulation, and drug leakage are also discussed, and related solutions are briefly proposed. Finally, the application prospects of nanoplatforms in the treatment of OS are discussed. |
format | Online Article Text |
id | pubmed-8885548 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-88855482022-03-02 Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma Wu, Kunzhe Yu, Beibei Li, Di Tian, Yangyang Liu, Yan Jiang, Jinlan Front Oncol Oncology Osteosarcoma (OS) is the most common primary bone tumor in children and young people. Traditional surgical excision combined with chemotherapy presents many limitations, such as resistance and systemic side effects of chemotherapy drugs, postoperative recurrence, and bone defects. Given these limitations, novel therapeutic modalities for OS treatment using nanometer-sized platform-based chemotherapeutic delivery have emerged as a promising alternative therapy. This form of therapy offers multiple advantages, such as accurate delivery of the drug to the tumor site and repair of limited bone defects after tumor resection. In this review, we briefly summarize nanoplatforms, including liposomes, polymeric nanoparticles, inorganic nanoparticles, nanomicelles, dendrimers, nanocapsules, and exosomes. The essential shortcomings involved in these nanoplatforms, such as poor stability, immunogenicity, insufficient circulation, and drug leakage are also discussed, and related solutions are briefly proposed. Finally, the application prospects of nanoplatforms in the treatment of OS are discussed. Frontiers Media S.A. 2022-02-15 /pmc/articles/PMC8885548/ /pubmed/35242707 http://dx.doi.org/10.3389/fonc.2022.805978 Text en Copyright © 2022 Wu, Yu, Li, Tian, Liu and Jiang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Wu, Kunzhe Yu, Beibei Li, Di Tian, Yangyang Liu, Yan Jiang, Jinlan Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma |
title | Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma |
title_full | Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma |
title_fullStr | Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma |
title_full_unstemmed | Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma |
title_short | Recent Advances in Nanoplatforms for the Treatment of Osteosarcoma |
title_sort | recent advances in nanoplatforms for the treatment of osteosarcoma |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885548/ https://www.ncbi.nlm.nih.gov/pubmed/35242707 http://dx.doi.org/10.3389/fonc.2022.805978 |
work_keys_str_mv | AT wukunzhe recentadvancesinnanoplatformsforthetreatmentofosteosarcoma AT yubeibei recentadvancesinnanoplatformsforthetreatmentofosteosarcoma AT lidi recentadvancesinnanoplatformsforthetreatmentofosteosarcoma AT tianyangyang recentadvancesinnanoplatformsforthetreatmentofosteosarcoma AT liuyan recentadvancesinnanoplatformsforthetreatmentofosteosarcoma AT jiangjinlan recentadvancesinnanoplatformsforthetreatmentofosteosarcoma |